Home' Australian Pharmacist : Australian Pharmacist May 2016 Contents Australian Pharmacist May 2016 I ©Pharmaceutical Society of Australia Ltd.
Liam wins Qld intern award
Liam Mendiolea is the PSA MIMS
Queensland Intern of the Year.
The Intern of the Year Award
acknowledges achievements of
exceptional pharmacist interns in
developing skills for their professional
career. Interns are recognised for
striving to raise standards to provide
a future model for the practice of
pharmacy, before being fully registered.
Liam began his internship in 2014 after
graduating with a Bachelor of Pharmacy
from James Cook University (JCU)
PSA Qld Branch Committee Chair
Andrew Petrie said Liam's achievements
demonstrated an outstanding
commitment to pharmacy.
'This important Award recognises an
exceptionally high-achieving intern and
proudly highlights his success. It clearly
shows the high standard of interns we
have in Australia,' Mr Petrie said.
MIMS Business Development Manager
Dinah Graham congratulated Liam and
said MIMS was delighted to be involved
in an Award that recognised the future
leaders of the pharmacy professional
The PSA MIMS Intern of the Year Award
will be chosen from the State/Territory
finalists, at PSA16 conference in Sydney
from July 29--31. The Award will go to the
finalist deemed to have created the most
significant innovation during the year.
An Australian systematic review and meta-analysis, to assess the risk of
venous thromboembolism (VTE) with the drospirenone-containing oral
contraceptive (OC), compared with those containing levonorgestrel and
other progestins, has concluded that the difference in risk, based on the
choice of progestin is, at worst, very small (in absolute terms)1,2 and should
not be the sole factor considered when GPs prescribe the 'right' oral
contraceptive type for woman.
The review was conducted by a local
group of reproductive and public health
experts. It reconfirms that the choice,
for women who are medically eligible3
to use an oestrogen-containing method
should be based on a range of factors,
including side-effect profile, potential
additional benefits, as well as cost and
Medical Director of Family Planning
NSW and lead author of the analysis,
Dr Deborah Bateson, said: 'The findings
of this robust, new meta-analysis can
now be used to support best practice
prescribing for women who prefer an
oral method of contraception. Although
retrospective studies have shown an
increased VTE risk with drospirenone-
containing oral contraceptives,
prospective studies, within this rigorous
review, have not shown this difference.
'Pharmacists need to be aware this
new Australian systematic review and
meta-analysis suggests that while
a difference in VTE risk cannot be
excluded with drospirenone-containing
oral contraceptives -- in absolute terms
any difference is likely to be very small,'
Dr Bateson said.
The review and meta-analysis of
available oral contraceptive studies
(prospective and retrospective)
identified a total of 15 eligible studies
for inclusion in the resulting analysis.2
Dr Bateson said: 'Pharmacists are often
a first port of call for women wanting
further information on contraceptive
options. It's important they keep up-to-
date and are aware all newly published
research -- which includes this Australian
meta-analysis which highlights that all
contraceptive pills on the market are a
safe option for women with no medical
'Critically, pharmacists need to be
fully across the data on VTE risk with
the contraceptive pill -- notably that
the absolute estimated risk of VTE is
4/10,000 women years for non-pregnant
non users and 7--10/10,000 women
years for those using oral contraceptives.
This is much lower than that attributed
to pregnancy or the post-partum period.'
1. Bateson D, et al. Risk of venous thromboembolism in
women taking the combined oral contraceptive. A
systematic review and meta-analysis. Aust Fam Phys.
2. Society of Obstetricians and Gynaecologists of Canada.
SOGC Clinical Practice Guideline: Oral contraceptives and
the risk of venous thromboembolism: an update. 2010.
3. The UK Medical Eligibility Criteria for Contraceptive Use
-- Nov 2009 (revised May 2010). Faculty of Sexual and
Reproductive Healthcare: Royal College of Obstetrics and
Gynaecology (UK). Accessed 22 Feb 2016.
Links Archive Australian Pharmacist April 2016 Australian Pharmacist June 2016 Navigation Previous Page Next Page